European journal of cancer (Oxford, England : 1990)
Jul 18, 2019
BACKGROUND: The diagnosis of most cancers is made by a board-certified pathologist based on a tissue biopsy under the microscope. Recent research reveals a high discordance between individual pathologists. For melanoma, the literature reports on 25-2...
European journal of cancer (Oxford, England : 1990)
May 23, 2019
BACKGROUND: The diagnosis of most cancers is made by a board-certified pathologist based on a tissue biopsy under the microscope. Recent research reveals a high discordance between individual pathologists. For melanoma, the literature reports 25-26% ...
European journal of cancer (Oxford, England : 1990)
May 17, 2019
The way we categorise and classify cancer types dictates not only the way we diagnose and treat patients but also many of our decisions on biomarker and drug development. In addition, cancer taxonomy proves the ground truth for future discoveries in ...
European journal of cancer (Oxford, England : 1990)
Apr 10, 2019
BACKGROUND: Recent studies have successfully demonstrated the use of deep-learning algorithms for dermatologist-level classification of suspicious lesions by the use of excessive proprietary image databases and limited numbers of dermatologists. For ...
European journal of cancer (Oxford, England : 1990)
Mar 8, 2019
BACKGROUND: Recent studies have demonstrated the use of convolutional neural networks (CNNs) to classify images of melanoma with accuracies comparable to those achieved by board-certified dermatologists. However, the performance of a CNN exclusively ...
European journal of cancer (Oxford, England : 1990)
Feb 22, 2019
BACKGROUND: Several recent publications have demonstrated the use of convolutional neural networks to classify images of melanoma at par with board-certified dermatologists. However, the non-availability of a public human benchmark restricts the comp...
European journal of cancer (Oxford, England : 1990)
Dec 7, 2018
BACKGROUND: Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma. Among the imaging parameters, contrast enhancement (CE) in WHO II...
European journal of cancer (Oxford, England : 1990)
Dec 21, 2017
BACKGROUND: Prior randomised controlled trials on adjuvant hormonal therapy included HER2 patients; however, a differential effect of aromatase inhibitors (AIs) versus tamoxifen (TAM) may have been missed in ER+/HER2+ patients that comprise 7-15% of ...